RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 96 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $147 | +14.0% | 101,278 | -15.0% | 0.00% | +33.3% |
Q3 2023 | $129 | -25.0% | 119,151 | -10.5% | 0.00% | 0.0% |
Q2 2023 | $172 | -11.3% | 133,179 | -9.4% | 0.00% | -40.0% |
Q1 2023 | $194 | -13.4% | 146,929 | -1.8% | 0.01% | -16.7% |
Q4 2022 | $224 | -99.9% | 149,606 | -23.3% | 0.01% | 0.0% |
Q3 2022 | $230,000 | -3.0% | 195,000 | -7.1% | 0.01% | -14.3% |
Q2 2022 | $237,000 | -73.4% | 210,000 | -29.5% | 0.01% | -66.7% |
Q1 2022 | $891,000 | -11.5% | 298,071 | -21.6% | 0.02% | -8.7% |
Q4 2021 | $1,007,000 | -31.7% | 380,000 | -6.5% | 0.02% | -28.1% |
Q3 2021 | $1,475,000 | -14.8% | 406,205 | +1.9% | 0.03% | -15.8% |
Q2 2021 | $1,731,000 | +31.1% | 398,783 | +3.3% | 0.04% | +31.0% |
Q1 2021 | $1,320,000 | -14.6% | 386,000 | -12.6% | 0.03% | -3.3% |
Q4 2020 | $1,546,000 | +30.5% | 441,760 | -10.5% | 0.03% | -6.2% |
Q3 2020 | $1,185,000 | +29.9% | 493,673 | -1.0% | 0.03% | +23.1% |
Q2 2020 | $912,000 | +21.4% | 498,539 | +3.5% | 0.03% | -10.3% |
Q1 2020 | $751,000 | -29.8% | 481,540 | -3.7% | 0.03% | +70.6% |
Q4 2019 | $1,070,000 | +12.2% | 500,000 | -2.0% | 0.02% | -10.5% |
Q3 2019 | $954,000 | -28.3% | 510,000 | 0.0% | 0.02% | -45.7% |
Q2 2019 | $1,331,000 | +1.5% | 510,000 | 0.0% | 0.04% | +6.1% |
Q1 2019 | $1,311,000 | +11.8% | 510,000 | 0.0% | 0.03% | -32.7% |
Q4 2018 | $1,173,000 | -26.2% | 510,000 | +3.0% | 0.05% | +16.7% |
Q3 2018 | $1,589,000 | +24.4% | 495,000 | +9.7% | 0.04% | +35.5% |
Q2 2018 | $1,277,000 | +33.6% | 451,100 | +67.1% | 0.03% | +3.3% |
Q1 2018 | $956,000 | -17.9% | 270,000 | -10.0% | 0.03% | 0.0% |
Q4 2017 | $1,164,000 | +572.8% | 300,000 | +341.2% | 0.03% | +400.0% |
Q3 2017 | $173,000 | -7.0% | 68,000 | 0.0% | 0.01% | -25.0% |
Q2 2017 | $186,000 | -19.8% | 68,000 | -2.9% | 0.01% | -11.1% |
Q1 2017 | $232,000 | +38.9% | 70,000 | 0.0% | 0.01% | +12.5% |
Q4 2016 | $167,000 | -39.3% | 70,000 | -6.7% | 0.01% | -52.9% |
Q3 2016 | $275,000 | -32.3% | 75,000 | -58.8% | 0.02% | -45.2% |
Q2 2016 | $406,000 | -36.0% | 182,250 | -40.2% | 0.03% | +10.7% |
Q1 2016 | $634,000 | -31.4% | 305,000 | 0.0% | 0.03% | -56.2% |
Q4 2015 | $924,000 | +23.0% | 305,000 | +0.3% | 0.06% | +93.9% |
Q3 2015 | $751,000 | -22.0% | 304,000 | +1.3% | 0.03% | -13.2% |
Q2 2015 | $963,000 | +17.3% | 300,000 | +30.4% | 0.04% | +5.6% |
Q1 2015 | $821,000 | +64.5% | 230,000 | +4.5% | 0.04% | +111.8% |
Q4 2014 | $499,000 | +71.5% | 220,000 | +46.7% | 0.02% | +142.9% |
Q3 2014 | $291,000 | -46.6% | 150,000 | 0.0% | 0.01% | -41.7% |
Q2 2014 | $545,000 | -6.4% | 150,000 | 0.0% | 0.01% | 0.0% |
Q1 2014 | $582,000 | +415.0% | 150,000 | +278.0% | 0.01% | +500.0% |
Q4 2013 | $113,000 | -32.3% | 39,683 | -20.6% | 0.00% | -60.0% |
Q2 2013 | $167,000 | – | 50,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |